Haemonetics (HAE) Stock Forecast & Price Target
Haemonetics (HAE) Analyst Ratings
Bulls say
Haemonetics Corp is experiencing strong financial momentum, with a projected FY25 operating margin of approximately 24%, reflecting consistent improvement from previous years. The company's gross margin has increased by 240 basis points year-over-year, and its operating margin has risen significantly by 390 basis points, demonstrating effective cost management and operational efficiency. Strong revenue growth in the plasma segment, driven by premium pricing and increased market share, alongside double-digit growth in transfusion management, underscores the company’s robust growth potential in key segments.
Bears say
Haemonetics Corp has experienced a decline in its Blood Center and Plasma segment sales, with Blood Center sales down 2.8% to $68.5 million and Plasma sales declining 9.1% to $138.6 million, both indicating a troubling trend in revenue generation. Additionally, the company's revised guidance for FY25 reflects lower growth expectations, projecting Hospital growth at 12-14%, down from 14-17%, and a significant adjustment in Blood Center growth expectations from a previous range of (3-6%) to (5-7%). Moreover, overall organic revenue growth has slowed to (0.3%) in F3Q25, compared to 3.7% in F2Q25, suggesting deteriorating operational performance and potential challenges in maintaining margins and earnings in the near future.
This aggregate rating is based on analysts' research of Haemonetics and is not a guaranteed prediction by Public.com or investment advice.
Haemonetics (HAE) Analyst Forecast & Price Prediction
Start investing in Haemonetics (HAE)
Order type
Buy in
Order amount
Est. shares
0 shares